The strategy of decreasing antimicrobial prescribing to reduce existing antimicrobial resistance appears attractive, but its effectiveness, particularly in the community setting, remains unclear. Contrasting results obtained from the relatively few studies in this area confuse matters further. Prescribing reductions have successfully reduced the prevalence of resistance among respiratory pathogens, but in these cases single bacterial clones dominated the resistant population. In contrast, this strategy has not succeeded in reducing plasmidencoded resistance among Escherichia coli. The reasons why some prescribing restriction policies are more successful than others are complex, with the three key determinants being the fitness cost of resistance, the clonal structure of the resistant bacterial population and co-selection of resistant organisms by other antimicrobials. The resistant bacterial phenotypes that are likely to be the easiest to eliminate will be those composed of relatively clonal populations that bear a fitness cost of resistance and are not significantly subjected to co-selection by other antimicrobials. Plasmid-encoded resistance seldom meets these criteria and, hence, is likely to be the most difficult to reduce.
Antimicrobial resistance remains a serious global heath concern and solutions to address it are urgently required. In light of the paucity of truly novel antimicrobials under development compared with the often rapid emergence of resistance, other, less costly strategies have been proposed. The concept of reducing antibiotic prescribing to reduce resistance has been considered a potentially viable alternative for the best part of two decades, the underlying rationale for this strategy being that antibiotic resistance will exert a fitness cost in the absence of antibiotic selection. 1 Hence, theoretically, when prescribing is reduced, less-fit resistant bacteria will be outcompeted and displaced by more-fit susceptible bacteria. However, the jury is still out on whether this strategy can be successfully employed to solve the resistance problem in practice.
The approach of reducing antimicrobial use has enjoyed fairly good success in reducing resistance when applied in relatively confined environments, such as hospital wards or in intensive farming. 2 -5 There are, nonetheless, some caveats, e.g. resistance to banned antimicrobials still persists at low levels in animal husbandry, 6 whilst in hospitals, restriction programmes can sometimes have undesirable effects by increasing the prescribing of other agents and subsequent resistance to them. 7 Often, reduction policies in hospitals and farming are aided by the ability to perform effective infection control and/or disinfection, thus creating a fresh niche for colonization by susceptible bacteria. Many such measures cannot be implemented in the community and, thus, the main tool available for reducing resistance there is the prescribing restriction itself.
The question of whether prescribing restrictions can bring about reductions in levels of antimicrobial resistance in the community remains wide open. It is complicated by the fact that opportunities to study the issue are few and far between. In some cases, countries or geographical regions have successfully brought in policies to control the prescribing of a particular antimicrobial agent, either to specifically study this question 8 or in response to a particular resistance problem. 9, 10 In other cases, retrospective studies have been undertaken to study the effects of prescribing restrictions brought in for other reasons (Figure 1 ). 11 -13 Perhaps the most successful example to date of a prescribing reduction policy to control resistance comes from Finland. During the late 1980s and early 1990s, erythromycin resistance among Streptococcus pyogenes isolates increased sharply from 5% in 1988 to a peak of 19% in 1993. 9 A recommendation to reduce macrolide consumption was issued in 1991 and resulted in a 63% decrease in macrolide use between 1988 (when use was highest) and 1994, after which use remained constant for several years. Resistance rates began declining after a time lag and had been reduced to 8.6% in 1996. 9 The majority of macrolide-resistant S. pyogenes isolates in Finland at the time belonged to a single dominant clone of the T4M4 serotype and had M-type macrolide resistance mediated by the mef(A) gene. Isolates representative of the clone were generally not resistant to other antimicrobials. 14, 15 A similar example exists from Iceland, where penicillin resistance among pneumococci rose sharply during the late 1980s and early 1990s from virtually negligible numbers to 19.8% in 1993. As a result, overall antibiotic use among children was reduced by 12.7% between 1992 and 1995, leading to a subsequent decrease in penicillin resistance by 25%. 10 The upsurge in resistance in Iceland was due to the spread of a single penicillin-resistant clone of Streptococcus pneumoniae. This was a multiresistant serotype 6B clone that had most probably been imported from Spain. 16 In contrast to these examples, reduced community prescribing has been much less successful in decreasing resistance among Escherichia coli. The current issue of JAC reports the findings from a recent Swedish study in which a 24 month intervention in trimethoprim use was performed in a single county (population 178000) to investigate the reversibility of resistance. 8 Unique and extremely detailed data on several aspects relating to the intervention were obtained. An 85% reduction in the use of trimethoprim-containing antimicrobials was achieved between 2004 and 2006. Data on antibiotic consumption and resistance were compared with those obtained pre-and postintervention as well as with data from a control county of a similar size, where no intervention was performed. The intervention had no effect on resistance to trimethoprim among E. coli isolates or among seven other bacterial species studied. Postintervention, trimethoprim use in the county returned to 79% of the pre-intervention level within 1 year. This increase in use was accompanied by an increase in trimethoprim resistance among E. coli, which was also paralleled in the control county where no intervention was performed. Investigation of the clonal structure of E. coli by phenotype analysis revealed no major changes in the distribution of E. coli phenotypes as a result of the intervention. Similarly, the distribution of the most common acquired trimethoprim resistance genes did not change. Trimethoprim resistance was frequently associated with resistance to other agents, such as ampicillin and fluoroquinolones, although single trimethoprim resistance also occurred. 8 Similar results were obtained during a retrospective analysis of the effect of a national prescribing restriction of trimethoprim/ sulfamethoxazole in the UK in 1995, due to perceived side effects of the sulphonamide. Despite a 97% reduction in use of all sulphonamide-containing antimicrobials, no change in rates of sulphonamide resistance among E. coli was observed. If anything, the prevalence of sulphonamide resistance increased slightly, being 39.7% prior to the restriction in 1991, 46.0% in 1999 and 45.5% in 2004, 11, 17 although the increase was not statistically significant. Clonality was not examined, but sulphonamide-resistant isolates were found to be frequently co-resistant to other agents. The sul2 gene was the most common sulphonamide resistance determinant and its prevalence increased during the study period.
Another, more positive recent study investigated urinary E. coli from Israel. A nationwide restriction on quinolone use was implemented in 2001/2 due to the need to preserve quinolones for treatment against a possible anthrax bioterrorism attack. The impact of the restriction was studied in a health district serving 167 000 people. A 7 month restriction on quinolone use resulted in a 28% reduction in prescribing compared with the preintervention period. The restriction resulted in a decrease in quinolone non-susceptibility among urinary E. coli from 12% to 9%. Figure 1 . Effect of prescribing reductions on the prevalence of antimicrobial resistance in the community. Each pair of columns indicates the percentage changes in the prescribing of antimicrobials and the corresponding effect on resistance prevalence on a per study basis: Finland, the effect of a macrolide reduction on macrolide resistance among S. pyogenes; 9 Iceland, the effect of overall reduced antimicrobial prescribing in children on penicillin resistance among S. pneumoniae;
10 Sweden, the effect of a trimethoprim reduction on trimethoprim resistance among E. coli; 8 the UK, the effect of a sulphonamide reduction on sulphonamide resistance among E. coli; 11 and Israel, the effect of a quinolone restriction on quinolone resistance among E. coli. 13 The timelines indicate the length of time during which the prescribing reductions and corresponding changes in resistance prevalence were measured.
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No change in b-lactam use or resistance was reported. Factors such as the mechanism(s) of quinolone resistance, clonality of the isolates or associated co-resistance were not studied. 13 The question that remains is why do some studies show a reduction in resistance in response to prescribing restriction, while others do not? At least three key themes emerge that appear significant: clonality of resistant isolates; co-selection; and the fitness cost of resistance. An additional factor that may influence the effectiveness of antimicrobial restriction policies is the influx of resistant organisms from other environments, such as other geographical areas or non-human hosts. However, once resistance is introduced, prevalence is more likely to be influenced by local selection pressures. The fact that resistance rates tend to show large geographical variations according to country or region tends to support this. 18 In the Finnish and Icelandic studies, where the most impressive reductions in resistance prevalence were achieved, the resistance problems were mainly caused by single successful clones. 14, 16 In contrast, in the study from Sweden, the resistant E. coli population was more diverse. 8 Thus, it appears easier to use reduced prescribing to eradicate a resistance problem mainly caused by a single clone, rather than one due to a polyclonal population. An important caveat should be remembered, i.e. the possibility that in the case of the Finnish and Icelandic studies, the observed reduction in resistance may have been due to the natural decline of the prevalent clones, rather than as a direct consequence of the antimicrobial restriction policies. Multiple known and unknown host and environmental factors can contribute to the success of particular clones and, hence, their demise (or indeed success) may not be related to antimicrobial prescribing, but could in fact occur for entirely different reasons.
Another key parameter influencing the reduction of antimicrobial resistance prevalence is co-selection. It is telling that in the Finnish example, the dominant clone was mainly resistant to a single class of antimicrobials, the macrolides.
14 This was also the class of antimicrobials for which prescribing was reduced. 9 In contrast, the Icelandic pneumococcus clone was multiresistant, 16 but in this case reduction in antimicrobial use was achieved for several antimicrobial classes. 10 The issue of co-selection becomes more important when the resistant organism to be eradicated is a Gram-negative species, such as E. coli, where the majority of resistance genes are plasmid-borne and frequently genetically linked to resistance determinants to other antimicrobial classes. Hence, the use of any antimicrobial to which a plasmid confers resistance is likely to select resistant bacteria. Indeed, co-selection by other antimicrobials was shown to be a key factor in the maintenance of resistance in studies from both Sweden and the UK. 8, 11 In the example from Israel, such data are not available; 13 however, despite the increasing spread of plasmid-borne quinolone resistance determinants, most clinically significant quinolone resistance in E. coli is still due to chromosomal mutations and is not closely genetically linked to resistance to other agents. 19 Perhaps the most critical parameter for the success of any prescribing reduction policy is likely to be the fitness cost of resistance. The successful studies from Finland, Iceland and Israel did not examine this aspect. However, penicillin resistance due to altered penicillin binding proteins has been shown to impose a fitness cost in several S. pneumoniae serotypes, including 6B, in a rat nasal colonization model. 20 Similarly, fluoroquinolone resistance in E. coli due to chromosomal mutations is often associated with a fitness cost. 21 The fitness cost of macrolide resistance due to acquired genes, such as mef(A), has not been examined in S. pyogenes or other bacteria. In contrast, no cost to trimethoprim resistance could be detected in E. coli isolates obtained during the Swedish study. 8 Similarly, whilst some plasmids encoding sulphonamide resistance from the UK study did confer a fitness cost, a sulphonamide resistance plasmid that actually enhanced host fitness was also described. Crucially, those plasmids that did confer a fitness cost would be expected to be maintained through co-selection with other antimicrobials still in clinical use. 22 Whilst initial studies investigating the fitness cost of plasmidborne resistance often demonstrated substantial fitness costs associated with plasmid carriage, 23 -26 more recent studies have shown that this is frequently not the case. Many resistance-encoding plasmids in fact confer relatively low or nonexistent fitness costs and may, on occasion, even enhance host fitness. 22,27 -29 This discrepancy may arise because early studies often looked at man-made cloning plasmids, frequently in laboratory-adapted strains, while more recent work has concentrated on naturally occurring plasmids. Of course, if there is no inherent fitness cost, or if the cost is very low, one would not expect antibiotic resistance to disappear, even if selection due to antibiotic use was reduced. 30 It therefore appears as if plasmid-encoded antibiotic resistance will be the most difficult to reduce. The fact that many plasmids will be maintained by co-selection with antimicrobials still in use further complicates the issue. Added to this, many plasmids are self-transmissible. Plasmids sometimes confer different fitness costs in different hosts 31 and, thus, by 'finding' the hosts in which fitness costs are lowest, self-transmissible plasmids will further strengthen their ability to survive changes in antibiotic selection pressure. Although it has been demonstrated that resistance plasmids can be transferred among bacteria in natural environments such as the human gut, 32 -34 the extent to which transfer occurs, and its overall effect on the prevalence and dynamics of antimicrobial resistance, is not well understood.
In summary, mankind clearly needs to do more to control the antibiotic resistance problem than simply reduce prescribing. While reduced prescribing has benefits, such as controlling the emergence and spread of new resistant bacteria, this strategy alone is not enough to reverse existing resistance in the community. However, policies to reduce resistance by restricting prescribing may be at least partially successful in certain circumstances. Before embarking on any such policy, it may be prudent to obtain as much information as possible about the resistance problem to be addressed, particularly the clonal composition of the bacterium, the genetic linkage of resistance determinants and the fitness cost of resistance. Additionally, more needs to be done to understand the dynamics of plasmid-borne resistance in the wild in order to ascertain whether or not prescribing reduction policies are likely to ever be successful in these cases and, if so, which types of policies are likely to have the highest degree of success.
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